|Dr. David Ross Parkinson M.D.||Chief Exec. Officer, Pres and Director||329.53k||N/A||67|
|Mr. David S. Wood MBA, CPA, CMA||Chief Financial Officer||N/A||N/A||60|
|Mr. Peter A. Virsik||Chief Operating Officer and Exec. VP||60.83k||N/A||46|
|Dr. Raymond Andersen Ph.D.||Chief Technical Officer, Sec. and Director||N/A||N/A||70|
|Dr. Marianne D. Sadar Ph.D.||Chief Scientific Officer and Director||N/A||N/A||56|
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.